AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now


  • AbbVie’s recent stock decline is a classic example of how valuation can greatly influence stock performance.
  • The pharma giant outperformed the analyst consensus for both net revenue and non-GAAP EPS in Q1.
  • AbbVie’s long-term debt remains A-rated by S&P on a stable outlook.
  • The company’s shares appear to be 1% overvalued.
  • I would be thinking about buying any dips a bit below $150.

American paper money, currency, cash dollars on white. Close-up. Finance, payment, trade, financial transactions concepts

$100 U.S. banknotes stacked over each other.

Iana Miroshnichenko

Investing can be as simple or as complicated as we make it. Those who know me know that I like to keep things as simple as possible.

In investing, three inputs

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ABBV either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Leave a Reply

Your email address will not be published. Required fields are marked *